Evidence map›Paper›PMID 38405909›Full record

ArticlebioRxiv : the preprint server for biology2024

YY1 mutations disrupt corticogenesis through a cell-type specific rewiring of cell-autonomous and non-cell-autonomous transcriptional programs.

Marlene F Pereira, Veronica Finazzi, Ludovico Rizzuti, Davide Aprile, Vittorio Aiello, Luca Mollica, Matteo Riva, Chiara Soriani, Francesco Dossena, Reinald Shyti and 8 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 4 countries.

Marlene F PereiraDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.ORCID 0000-0002-8890-2994
Veronica FinazziHuman Technopole, Viale Rita Levi-Montalcini 1, 20157, Milan, Italy.ORCID 0009-0006-7708-1832
Ludovico RizzutiDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.ORCID 0000-0002-9807-8150
Davide AprileHuman Technopole, Viale Rita Levi-Montalcini 1, 20157, Milan, Italy.ORCID 0000-0003-3791-5629
Vittorio AielloDepartment of Oncology and Hemato-Oncology, University of Milan, Via Santa Sofia 9, 20122, Milan, Italy.
Luca MollicaDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Italy.ORCID 0000-0001-5403-9507
Matteo RivaDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Italy.
Chiara SorianiDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.ORCID 0000-0003-4363-6597
Francesco DossenaHuman Technopole, Viale Rita Levi-Montalcini 1, 20157, Milan, Italy.ORCID 0009-0005-4948-4805
Reinald ShytiDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.ORCID 0000-0002-1888-8656
Davide CastaldiDepartment of Oncology and Hemato-Oncology, University of Milan, Via Santa Sofia 9, 20122, Milan, Italy.ORCID 0000-0002-9055-0801
Erika TenderiniDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.ORCID 0000-0002-4073-8259
Maria Teresa Carminho-RodriguesDepartment of Genetics, University of Geneva & University Hospitals of Geneva, Geneva, Switzerland.ORCID 0000-0001-5678-2505
Julien F BallyService of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital & University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-0970-8844
Bert B A de VriesRadboud University UMC, Nijmegen, The Netherlands.ORCID 0000-0002-0000-2917
Michele GabrieleDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.ORCID 0000-0002-5393-9084
Alessandro VitrioloDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.ORCID 0000-0002-1462-8064
Giuseppe TestaDepartment of Experimental Oncology, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.ORCID 0000-0002-9104-0918
University of Milan · ITHuman Technopole · ITBroad Institute · USEuropean Institute of Oncology · ITRadboud University Nijmegen · NLTelethon Institute Of Genetics And Medicine · ITUniversity of Geneva · CHUniversity of Lausanne · CH

Funding

Dissecting enhancer-promoter looping and gene induction dynamics in differentiationK99GM149815 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GABRIELE, MICHELE · 2023 to 2024
$250k
NIGMS NIH HHS K99 GM149815
6 · The paper itself

Abstract

Germline mutations of YY1 cause Gabriele-de Vries syndrome (GADEVS), a neurodevelopmental disorder featuring intellectual disability and a wide range of systemic manifestations. To dissect the cellular and molecular mechanisms underlying GADEVS, we combined large-scale imaging, single-cell multiomics and gene regulatory network reconstruction in 2D and 3D patient-derived physiopathologically relevant cell lineages. YY1 haploinsufficiency causes a pervasive alteration of cell type specific transcriptional networks, disrupting corticogenesis at the level of neural progenitors and terminally differentiated neurons, including cytoarchitectural defects reminiscent of GADEVS clinical features. Transcriptional alterations in neurons propagated to neighboring astrocytes through a major non-cell autonomous pro-inflammatory effect that grounds the rationale for modulatory interventions. Together, neurodevelopmental trajectories, synaptic formation and neuronal-astrocyte cross talk emerged as salient domains of YY1 dosage-dependent vulnerability. Mechanistically, cell-type resolved reconstruction of gene regulatory networks uncovered the regulatory interplay between YY1, NEUROG2 and ETV5 and its aberrant rewiring in GADEVS. Our findings underscore the reach of advanced in vitro models in capturing developmental antecedents of clinical features and exposing their underlying mechanisms to guide the search for targeted interventions.

Identifiers

PMID38405909
PMCPMC10888784
OpenAlexW4391897092

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.